Advertisement

LH-RH Agonists in the Treatment of Premenopausal Patients with Advanced Breast Cancer

  • K. Höffken
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 124)

Abstract

Ovarian ablation has a long-standing history in the treatment of metastatic breast cancer. At the end of the last century, Schinzinger [34] and Beatson [1] independently reported on the beneficial effect of surgical removal of the ovaries in premenopausal women with advanced breast cancer. Subsequently, this treatment became the standard systemic hormonal therapy in such patients.

Keywords

Breast Cancer Metastatic Breast Cancer Advanced Breast Cancer Premenopausal Patient Premenopausal Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beatson GT (1896) On the treatment in operablic cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases Lancet 2:104–107, 162-165CrossRefGoogle Scholar
  2. 2.
    Buchanan RB, Blarney RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326–1330PubMedGoogle Scholar
  3. 3.
    Conte CC, Nemoto T, Rosner D, Dao TL (1989) Therapeutic oophorectomy in metastatic breast cancer. Cancer 64:150–153PubMedCrossRefGoogle Scholar
  4. 4.
    Eidne KA, Flanagan CA, Harris NS, Millar RP (1987) Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64:425–32PubMedCrossRefGoogle Scholar
  5. 5.
    Foekens JA, Henkelman MS, Bolt-deVries J, Portengen H, Fukkink JF, Blankenstein MA, van Steenbrugge GJ, Mulder E, Klijn JGM (1987) Direct effects of LHRH analogs on breast and prostatic tumor cells. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factor, and new (anti) steroidal agents. Monograph Series of the European Organization for Research on Treatment of Cancer (EORTC) 18:369–380Google Scholar
  6. 6.
    Foekens JA, Henkelman MS, Fukkink JF, Blankenstein MA, Klijn JGM (1986) Direct effects of LHRH analogs on tumor cells. Eur J Cancer 22:(Abstr III-s), 725Google Scholar
  7. 7.
    Hardt W, Schmidt GM (1983) Sustained gonadal suppression in fertile women with the LHRH agonist buserelin. Clin Endocrinol Oxf 19:613–7PubMedCrossRefGoogle Scholar
  8. 8.
    Harvey HA, Lipton A, Max DT, Pearlman OHG, Diaz-Perches R, de la Garza J (1984) Effective medical castration produced by the GnRH analog Leuprolide in metastatic breast cancer. Proc Amer Soc Clin Oncol 3:(Abstr C-435), 111Google Scholar
  9. 9.
    Harvey HA, Lipton A, Max DT, Perlman OHG, Diaz-Perches R, de la Garza J (1985) Medical castration produced by the GnRH analog leuprolide to treat metastatic breast cancer. J Clin Oncol 3:1086–1072Google Scholar
  10. 10.
    Harvey HA, Lipton A, Santen RJ, Escher GC, Hardy MA, Glode LM, Sealoff A, Landau RL, Schneir H, Max DT (1981) Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer patients. Proc Am Assoc Cancer Res & Amer Soc Clin Oncol 22:(Abstr C-436), 444Google Scholar
  11. 11.
    Hayward HA, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13:89–94Google Scholar
  12. 12.
    Henderson IC, Cannelos GP (1980) Cancer of the breast: the past decade. N Engl J Med 302:17–30, 78-90PubMedCrossRefGoogle Scholar
  13. 13.
    Höffken K (1988) LH-RH agonists in oncology. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  14. 14.
    Höffken K, Oesterdickhoff C, Becher R, Callies R, Kurschel E, Anders CU, Scheulen ME, Schmidt CG (1989) LH-RH agonist treatment with buserelin in premenopausal patients with advanced breast cancer: a phase II study. Cancer Ther Control 1:13–20Google Scholar
  15. 15.
    Hoogstraten B, Fletcher WS, Gad-el-Mawla N, Maloney TR, Altman SJ, Vaughn CB, Foulkes MA (1982) Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. A southwest oncology group study. Cancer Res 42:4788–4791PubMedGoogle Scholar
  16. 16.
    Hoogstraten B, Gad-el-Mawla N, Maloney TR, Fletcher WS, Vaughn CB, Tranum BL, Athens JW, Costanzi JJ, Foulkes M (1984) Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study. Cancer 54:2248–2256PubMedCrossRefGoogle Scholar
  17. 17.
    Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, Chang MN, Bisel HF, Windschitl HE, Twito DI, Pfeifle DM (1986) Randomized trial of bilateral oophrec-tomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178–185PubMedGoogle Scholar
  18. 18.
    Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Jänicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel HK, Schmid H, Strunz P, Schachner-Wünschmann E, Bastert G, Maass H (1989) Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7:1113–1119PubMedGoogle Scholar
  19. 19.
    Klijn JGM (1984) Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med Oncol Tumor Pharmacother 1:123–8PubMedGoogle Scholar
  20. 20.
    Klijn JGM, de Jong FH (1982) Treatment with a luteinizing hormone-releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1:1213–1216PubMedCrossRefGoogle Scholar
  21. 21.
    Klijn JGM, de Jong FH (1987) Long-term LHRH-agonist (Buserelin) treatment in metastatic premenopausal breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Monograph Series of the European Organization for Research on Treatment of Cancer (EORTC) 18:343–352Google Scholar
  22. 22.
    Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein MA (1985) LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23:867–873PubMedCrossRefGoogle Scholar
  23. 23.
    Klijn JGM, Paridaens R, Foekens JA (1987) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Monograph Series of the European Organization for Research on Treatment of Cancer (EORTC) 18Google Scholar
  24. 24.
    Legha SS, Davis HL, Muggia FM (1978) Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med 88:69–77PubMedGoogle Scholar
  25. 25.
    Manni A, Pearson OH (1976) Antiestrogen-induced remissions in stage IV breast cancer. Cancer Treat Rep 60:1445–1450PubMedGoogle Scholar
  26. 26.
    Manni A, Pearson OH (1980) Antiestrogen-induced remission in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64:779–785PubMedGoogle Scholar
  27. 27.
    Nicholson RI, Maynard PV (1979) Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer 39:268–273PubMedCrossRefGoogle Scholar
  28. 28.
    Planting AST, Alexieva-Figusch J, Blonk-vdWist J, van Putten WLJ (1985) Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat Rep 69:363–368PubMedGoogle Scholar
  29. 29.
    Plowman PN, Nicholson RI, Walker KJ (1986) Remissions of metastatic breast cancer in postmenopausal women with luteinizing hormone releasing hormone (ICI 118630) therapy. Eur J Cancer 22:746 (Abstract 111-18)Google Scholar
  30. 30.
    Pritchard KI, Thomson DB, Myers RE, Sutherland D, Mobb BG, Meakin JW (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64:787–796PubMedGoogle Scholar
  31. 31.
    Sandow J, Fraser HM, Seidel H, Krauss B, Jarabek-Sandow G, Von Rechenberg W (1987) Buserelin: pharmacokinetics, metabolism and mechanisms of action. Br J Clin Pract 41:6–13Google Scholar
  32. 32.
    Schacter LP, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L (1990) Overview of hormonal therapy in advanced breast cancer. Semin Oncol 17:38–46PubMedGoogle Scholar
  33. 33.
    Schally AV, Redding TW, Comaru SA (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68:281–289PubMedGoogle Scholar
  34. 34.
    Schinzinger AS (1889) Über Carcinoma mammae. Zbl Chir (Beil) 16:55–56Google Scholar
  35. 35.
    Waxman JH, Harland SJ, Coombes RC, Wrigley P, Malpas JS, Powles T, Lister TA (1985) The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 15:171–173PubMedCrossRefGoogle Scholar
  36. 36.
    Williams MR, Walker KJ, Turkes A, Blarney RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53:629–636PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • K. Höffken
    • 1
  1. 1.Innere Klinik und Poliklinik (Tumorforschung)Universitätsklinikum EssenEssenFRG

Personalised recommendations